Screening of H-ras gene point mutations in 50 cases of bladder carcinoma

Shiro Saito, Makoto Hata, Ryuichi Fukuyama, Kosuke Sakai, Jun Kudo, Hiroshi Tazaki, Nobuyoshi Shimizu

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Mutation converts the H-ras gene into an activated oncogene in about 10% of human bladder cancers. Codons 12 and 61 are the major 'hot spots' for activation. A simple and accurate method to detect point mutations in these codons may be clinically useful for early diagnosis of bladder cancer. Methods: Bladder cancer samples from 50 patients, plus 10 samples of normal bladder mucosa, were analyzed for possible point mutation of the H-ras gene at either codon 12 or codon 61. The H-ras gene DNA segments that include these 2 codons were amplified by PCR methods, then the possible presence of a point mutation was evaluated at each codon by susceptibility of the respective DNA segments to digestion with the restriction enzyme and by dot blot hybridization assay. A bladder cancer patient who had an H-ras gene mutation was examined to see whether the mutation was also detectable in the cells released in the urine. Results: Definite or possible point mutations were found in 6 (12%) out of 50 bladder cancer patients, while no mutation was detected in normal mucosa. A point mutation could also be detected in cells isolated from the patient's urine sample. Conclusion: The prevalence of point mutations at codon 12 or codon 61 of the H-ras gene found in this study was similar to that previously estimated for human bladder cancer by DNA transfection assay. The method we have used for detecting point mutations of the H-ras gene provides a simple and highly accurate way to detect mutated cancer cells even in the urine. It may be clinically usable for early diagnosis of bladder cancer.

Original languageEnglish
Pages (from-to)178-185
Number of pages8
JournalInternational Journal of Urology
Volume4
Issue number2
Publication statusPublished - 1997

Fingerprint

ras Genes
Point Mutation
Codon
Urinary Bladder Neoplasms
Urinary Bladder
Carcinoma
Mutation
Urine
Early Detection of Cancer
DNA
Mucous Membrane
Oncogenes
Transfection
Digestion
Polymerase Chain Reaction
Enzymes

Keywords

  • Bladder neoplasms
  • Diagnosis
  • H-ras oncogene
  • Point mutation

ASJC Scopus subject areas

  • Urology

Cite this

Saito, S., Hata, M., Fukuyama, R., Sakai, K., Kudo, J., Tazaki, H., & Shimizu, N. (1997). Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. International Journal of Urology, 4(2), 178-185.

Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. / Saito, Shiro; Hata, Makoto; Fukuyama, Ryuichi; Sakai, Kosuke; Kudo, Jun; Tazaki, Hiroshi; Shimizu, Nobuyoshi.

In: International Journal of Urology, Vol. 4, No. 2, 1997, p. 178-185.

Research output: Contribution to journalArticle

Saito, S, Hata, M, Fukuyama, R, Sakai, K, Kudo, J, Tazaki, H & Shimizu, N 1997, 'Screening of H-ras gene point mutations in 50 cases of bladder carcinoma', International Journal of Urology, vol. 4, no. 2, pp. 178-185.
Saito S, Hata M, Fukuyama R, Sakai K, Kudo J, Tazaki H et al. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. International Journal of Urology. 1997;4(2):178-185.
Saito, Shiro ; Hata, Makoto ; Fukuyama, Ryuichi ; Sakai, Kosuke ; Kudo, Jun ; Tazaki, Hiroshi ; Shimizu, Nobuyoshi. / Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. In: International Journal of Urology. 1997 ; Vol. 4, No. 2. pp. 178-185.
@article{029ffde369d949c982e62df2da37240b,
title = "Screening of H-ras gene point mutations in 50 cases of bladder carcinoma",
abstract = "Background: Mutation converts the H-ras gene into an activated oncogene in about 10{\%} of human bladder cancers. Codons 12 and 61 are the major 'hot spots' for activation. A simple and accurate method to detect point mutations in these codons may be clinically useful for early diagnosis of bladder cancer. Methods: Bladder cancer samples from 50 patients, plus 10 samples of normal bladder mucosa, were analyzed for possible point mutation of the H-ras gene at either codon 12 or codon 61. The H-ras gene DNA segments that include these 2 codons were amplified by PCR methods, then the possible presence of a point mutation was evaluated at each codon by susceptibility of the respective DNA segments to digestion with the restriction enzyme and by dot blot hybridization assay. A bladder cancer patient who had an H-ras gene mutation was examined to see whether the mutation was also detectable in the cells released in the urine. Results: Definite or possible point mutations were found in 6 (12{\%}) out of 50 bladder cancer patients, while no mutation was detected in normal mucosa. A point mutation could also be detected in cells isolated from the patient's urine sample. Conclusion: The prevalence of point mutations at codon 12 or codon 61 of the H-ras gene found in this study was similar to that previously estimated for human bladder cancer by DNA transfection assay. The method we have used for detecting point mutations of the H-ras gene provides a simple and highly accurate way to detect mutated cancer cells even in the urine. It may be clinically usable for early diagnosis of bladder cancer.",
keywords = "Bladder neoplasms, Diagnosis, H-ras oncogene, Point mutation",
author = "Shiro Saito and Makoto Hata and Ryuichi Fukuyama and Kosuke Sakai and Jun Kudo and Hiroshi Tazaki and Nobuyoshi Shimizu",
year = "1997",
language = "English",
volume = "4",
pages = "178--185",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Screening of H-ras gene point mutations in 50 cases of bladder carcinoma

AU - Saito, Shiro

AU - Hata, Makoto

AU - Fukuyama, Ryuichi

AU - Sakai, Kosuke

AU - Kudo, Jun

AU - Tazaki, Hiroshi

AU - Shimizu, Nobuyoshi

PY - 1997

Y1 - 1997

N2 - Background: Mutation converts the H-ras gene into an activated oncogene in about 10% of human bladder cancers. Codons 12 and 61 are the major 'hot spots' for activation. A simple and accurate method to detect point mutations in these codons may be clinically useful for early diagnosis of bladder cancer. Methods: Bladder cancer samples from 50 patients, plus 10 samples of normal bladder mucosa, were analyzed for possible point mutation of the H-ras gene at either codon 12 or codon 61. The H-ras gene DNA segments that include these 2 codons were amplified by PCR methods, then the possible presence of a point mutation was evaluated at each codon by susceptibility of the respective DNA segments to digestion with the restriction enzyme and by dot blot hybridization assay. A bladder cancer patient who had an H-ras gene mutation was examined to see whether the mutation was also detectable in the cells released in the urine. Results: Definite or possible point mutations were found in 6 (12%) out of 50 bladder cancer patients, while no mutation was detected in normal mucosa. A point mutation could also be detected in cells isolated from the patient's urine sample. Conclusion: The prevalence of point mutations at codon 12 or codon 61 of the H-ras gene found in this study was similar to that previously estimated for human bladder cancer by DNA transfection assay. The method we have used for detecting point mutations of the H-ras gene provides a simple and highly accurate way to detect mutated cancer cells even in the urine. It may be clinically usable for early diagnosis of bladder cancer.

AB - Background: Mutation converts the H-ras gene into an activated oncogene in about 10% of human bladder cancers. Codons 12 and 61 are the major 'hot spots' for activation. A simple and accurate method to detect point mutations in these codons may be clinically useful for early diagnosis of bladder cancer. Methods: Bladder cancer samples from 50 patients, plus 10 samples of normal bladder mucosa, were analyzed for possible point mutation of the H-ras gene at either codon 12 or codon 61. The H-ras gene DNA segments that include these 2 codons were amplified by PCR methods, then the possible presence of a point mutation was evaluated at each codon by susceptibility of the respective DNA segments to digestion with the restriction enzyme and by dot blot hybridization assay. A bladder cancer patient who had an H-ras gene mutation was examined to see whether the mutation was also detectable in the cells released in the urine. Results: Definite or possible point mutations were found in 6 (12%) out of 50 bladder cancer patients, while no mutation was detected in normal mucosa. A point mutation could also be detected in cells isolated from the patient's urine sample. Conclusion: The prevalence of point mutations at codon 12 or codon 61 of the H-ras gene found in this study was similar to that previously estimated for human bladder cancer by DNA transfection assay. The method we have used for detecting point mutations of the H-ras gene provides a simple and highly accurate way to detect mutated cancer cells even in the urine. It may be clinically usable for early diagnosis of bladder cancer.

KW - Bladder neoplasms

KW - Diagnosis

KW - H-ras oncogene

KW - Point mutation

UR - http://www.scopus.com/inward/record.url?scp=0030937967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030937967&partnerID=8YFLogxK

M3 - Article

C2 - 9179693

AN - SCOPUS:0030937967

VL - 4

SP - 178

EP - 185

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 2

ER -